Vical Licensee Sanofi-aventis Completes Enrollment in Phase 3 Angiogenesis Trial
SAN DIEGO, Sept. 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's licensee, sanofi-aventis, has confirmed the completion of enrollment in a multinational 500-patient pivotal Phase 3 clinical trial of its angiogenesis therapy based on Vical's non-viral DNA delivery technology. Sanofi-aventis expects final data from this trial in late 2010.
"We are pleased that sanofi-aventis, one of our two partners in the angiogenesis field, has advanced according to plan with the Phase 3 testing of this novel therapy," said Vijay B. Samant, Vical's President and Chief Executive Officer, "and we would expect timely trial completion. Angiogenesis is among the most promising near-term human applications of our DNA delivery technology, and represents a substantial potential market for which there is no adequate therapy. The ability of plasmid DNA to induce production of angiogenesis protein locally at the site of injection ideally matches the desired treatment profile for peripheral vascular disease."
No Name Ninja